Part,  Chapter, Paragraph

  1    I,     2. 10.  3(6) |                Session 2006, Report I (C). ILO, Geneva.~
  2    I,     2. 10.  3(7) |                                Freeman C, Soete L, Efendioglu U (
  3    I,     2. 11        |           Available at: htt df~Freeman C, Soete L, Efendioglu U (
  4    I,     2. 11        |                Session 2006, Report I (C): ILO, Geneva~Marrone S (
  5    I,     2. 11        |               Jun;66(3):188-98.~Medina c. et al. (2007): Nanoparticles:
  6   II,     4.  3        |               COM(2005): 24.~ ~Jagger, C. and EHEMU Team (2005):
  7   II,     4.  3        |               and Welfare.~ ~Riley, J. C. (1990): The risk of being
  8   II,     4.  3        |               432.~ ~Robine, J.-M. and C. Jagger (2007): Healthy
  9   II,     4.  3        |               328.~ ~Robine, J.-M. and C. Jagger (2007): Strategic
 10   II,     4.  3        |                Inserm~ ~Robine, J.-M., C. Jagger, et al. (2002):
 11   II,     4.  3        |              119-133.~ ~Robine, J.-M., C. Jagger, et al. (2003):
 12   II,     4.  3        |                 6-14.~ ~Robine, J.-M., C. Jagger, et al., Eds. (2003):
 13   II,     4.  3        |             Sons.~ ~Robine J-M, Jagger C, and the Euro-REVES Group (
 14   II,     4.  3        |              13:6-14.~ ~Robine, J.-M., C. Jagger, et al. (2001):
 15   II,     5.  1.  1    |         hyperphosphatemia, high plasma C Reactive Protein and Fibrinogen,
 16   II,     5.  1.  1    |         disease, i.e., hepatitis B and C virus (HBV and HCV) infection
 17   II,     5.  2.  6    |       morbidity and mortality (Baigent C et al, 2005). The available
 18   II,     5.  2.  6    |                found in 5.2.7)~Baigent C, Keech A, Kearney PM, Blackwell
 19   II,     5.  2.  6    |         Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto
 20   II,     5.  2.  6    |            1571-1576.~Keys A, Aravanis C, Blackburn HW, Van Buchem
 21   II,     5.  2.  7    |               Palmieri L, Donfrancesco C, Giampaoli S, Trojani M,
 22   II,     5.  2.  7    |               Palmieri L, Donfrancesco C, Vanuzzo D, Chiodini P,
 23   II,     5.  2.  7    |             Heart J 18: 1231–48.~Sarti C, Stegmayr B, Tolonen H,
 24   II,     5.  3.  9    |              Sant M, Storm H, Allemani C, Ciccolallo L, Santaquilani
 25   II,     5.  3.  9    |               G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani
 26   II,     5.  3.  9    |                 Capocaccia R, Martinez C, Mugno E, Coebergh JW, Baili
 27   II,     5.  4.  8    |         diabetes. The EURODIAB Subarea C Study Group Epidemiology.;
 28   II,     5.  4.  8    |            Pruna A, Ionescu-Tirgoviste C. (2002), A networked electronic
 29   II,     5.  5.Int(15)|         Delespaul P, Fuhrer R, Hooijer C, Lawlor BA, Kivela S-L,
 30   II,     5.  5.Int(15)|           Roelands M, Skoog I, Turrina C, deVries MW, Wilson KCM (
 31   II,     5.  5.  1    |                76.~ ~Kessler R, Nelson C, McGonagle K, Liu G (1996):
 32   II,     5.  5.  1    |                Haro JM, Sevilla-Dedieu C, the ESEMeD/MHEDEA 2000
 33   II,     5.  5.  2    |          Eastern Europe (Regions B and C)23. ~ ~Apart from the methodological
 34   II,     5.  5.  2(23)|                and Turkey and the EURO C category, those with a high
 35   II,     5.  5.  2    |            Godfrey M, Townsend J, Surr C, Boyle G and Brooker D (
 36   II,     5.  5.  3    |               R.G, Sjöström M, Hillger C, Neumann G, Kirch W (in
 37   II,     5.  5.  3    |                D.; Lohr, K. N.; Bulik, C. M. (2007): Outcomes of
 38   II,     5.  5.  3    |             Gonzalez-Gross M, Leclercq C, Kafatos A, Molnar D, Marcos
 39   II,     5.  5.  3    |               K, Manios Y, Breidenasse C, Kersting M, Moreno LA,
 40   II,     5.  5.  3    |                A Miller, K.K, Almazan, C, Worley, M,. Soyka, L.A,
 41   II,     5.  5.  3    |       Sandersson K, Corry J, Issakidis C, Lapsley H (2003): Cost-effectiveness
 42   II,     5.  5.  3    |           Psychiatry 171:502-8.~Buizza C, Schulze B, Bertocchi E,
 43   II,     5.  5.  3    |         Medina-Mora ME, Borges G, Lara C, de Graaf R, Ormel J, Gureje
 44   II,     5.  5.  3    |             Bromet EJ, Gluzman S, Webb C, Kessler RC, Merikangas
 45   II,     5.  5.  3    |                 Parsch JR, Ebenbichler C (2006): Antipsychotic drug-induced
 46   II,     5.  5.  3    |                 229-30.~Holt RI, Bushe C, Citrome L (2005): Diabetes
 47   II,     5.  5.  3    |           Leucht S, Stiegler M, Rummel C, Wahlbeck K, Kissling W (
 48   II,     5.  5.  3    |             Geddes J, Orbach G, Morgan C (2002): Psychological treatments
 49   II,     5.  5.  3    |              Jacoby A, Gorry J, Gamble C, Baker GA (2004): Public
 50   II,     5.  5.  3    |               672.~Vignatelli L, Tonon C, DAlessandro R, on behalf
 51   II,     5.  5.  3    |            benign and/or early cases; (c) the different degree of
 52   II,     5.  5.  3    |               continuing progression; (c) secondary-progressive MS (
 53   II,     5.  5.  3    |              115-122.~Bencsik K, Rajda C, Füvesi J, et al (2001):
 54   II,     5.  5.  3    |           Neurol 8:463-469.~Confavreux C, Compston DA, Hommes OR,
 55   II,     5.  5.  3    |       Psychiatr 55:671–676.~Confavreux C (1994): Establishment and
 56   II,     5.  5.  3    |           suppl):S136–S139.~Confavreux C, Vukusic S, Moreau T, et
 57   II,     5.  5.  3    |              343:1430–1438.~Confavreux C, Vukusic S, Adeleine P (
 58   II,     5.  5.  3    |              Scler 7:111-117.~McGuigan C, McCarthy A, Quigley C,
 59   II,     5.  5.  3    |        McGuigan C, McCarthy A, Quigley C, et al (2004): Latitudinal
 60   II,     5.  5.  3    |             Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker
 61   II,     5.  5.  3    |   Neuroepidemiology 5:71-79.~Pritchard C, Baldwin D, Mayers A (2004).
 62   II,     5.  5.  3    |              170-174.~Totaro R, Marini C, Cialfi A, et al (2000):
 63   II,     5.  5.  3    |                 Gosselin S, Confavreux C (2007): Regional variations
 64   II,     5.  5.  3    |                13(4):626-632.~Anderson C, Checkoway H, Franklin GM,
 65   II,     5.  5.  3    |                de Munain A, Sarasqueta C, de Arce A, Poza JJ, Marti-Masso
 66   II,     5.  5.  3    |               M, Poskanzer DC, Rolland C, Miller H (1966): Neurological
 67   II,     5.  5.  3    |               147-151.~Chio A, Magnani C, Schiffer D (1998): Prevalence
 68   II,     5.  5.  3    |               Perez-Sempere A, Cabezas C, Rodriguez F, de Pedro-Cuesta
 69   II,     5.  5.  3    |              2146.~de Rijk MC, Tzourio C, Breteler MM, Dartigues
 70   II,     5.  5.  3    |                128.~Elbaz A, Tranchant C (2007): Epidemiologic studies
 71   II,     5.  5.  3    |                Errea JM, Ara JR, Aibar C, de Pedro-Cuesta J (1999):
 72   II,     5.  5.  3    |                Bain PG, Baker M, Beech C, Bowman C, Holmes J, Kingdom
 73   II,     5.  5.  3    |               Baker M, Beech C, Bowman C, Holmes J, Kingdom WK, MacMahon
 74   II,     5.  5.  3    |             Poewe W, Rascol O, Sampaio C (2006): Review of the therapeutic
 75   II,     5.  5.  3    |             Disord 8(5):297-309.~LePen C, Wait S, Moutard-Martin
 76   II,     5.  5.  3    |           Ben-Shlomo Y, Lees A, Rooney C, Burn D (2005): Population
 77   II,     5.  5.  3    |                Riederer P, Trenkwalder C, Dodel R, Wittchen HU (2008):
 78   II,     5.  5.  3    |                D, Perkins KS, Counsell C (2003): Systematic review
 79   II,     5.  5.  3    |              Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert
 80   II,     5.  6.  6    |       Ejlertsson G, Leden I, Rosenberg C (1993): Chronic pain in
 81   II,     5.  6.  6    |              Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F,
 82   II,     5.  6.  6    |           Rheum Dis 66(1):34-45~Cooper C (1997): The crippling consequences
 83   II,     5.  6.  6    |               J Med 103:12S-17S~Cooper C, Atkinson EJ, Jacobsen SJ,
 84   II,     5.  6.  6    |         Epidemiol 137:1001-1005~Cooper C, Melton LJ, III (1992):
 85   II,     5.  6.  6    |            Coggon D, Cruddas M, Cooper C (1992): Osteoarthritis of
 86   II,     5.  6.  6    |           Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004):
 87   II,     5.  6.  6    |                I, Petterson C, De Laet C, Jonsson B (2004): Mortality
 88   II,     5.  6.  6    |             Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002):
 89   II,     5.  6.  6    |             Oden A, Jonsson B, De Laet C, Dawson A (2000): Risk of
 90   II,     5.  6.  6    |               Epidemiol 111:87-98~Lock C, Allgar V, Jones K, Marples
 91   II,     5.  6.  6    |           Jones K, Marples G, Chandler C, Dawson P (1999): Prevalence
 92   II,     5.  6.  6    |            Minshall ME, Shen W, Cooper C, Kanis J (2000): Health-related
 93   II,     5.  6.  6    |               27-48~O'Neill TW, Cooper C, Finn JD, Lunt M, Purdie
 94   II,     5.  6.  6    |             Walsh K, Bendall H, Cooper C, Coggon D (2000) Back pain
 95   II,     5.  6.  6    |             835-843~Symmons D, Mathers C, and Pfleger B (2003): Global
 96   II,     5.  6.  6    |                EM, Leufkens HG, Cooper C (2001): Epidemiology of
 97   II,     5.  6.  6    |                Mosby-Elsevier; Section C, Chapter 1.~Zollman C, Vickers
 98   II,     5.  6.  6    |          Section C, Chapter 1.~Zollman C, Vickers A (1999): ABC of
 99   II,     5.  7.  4    |         hyperphosphatemia, high plasma C Reactive Protein and Fibrinogen,
100   II,     5.  7.  7    |                 Asselbergs FW, Boersma C, de Vries R, Hillege HL,
101   II,     5.  7.  7    |                2006;28:432-44.~Baigent C, Burbury K, Wheeler D (2000):
102   II,     5.  7.  7    |               M, Zanchetti A, Lombardi C, De Santo NG (2006): Low
103   II,     5.  7.  7    |              678-80.~Jager KJ, Zoccali C (2007): Clinical databases
104   II,     5.  7.  7    |              21(7):1899-905.~Meisinger C, Doring A, Lowel H (2006):
105   II,     5.  7.  7    |            Culleton B, House A, Rabbat C, Fok M, et al (2006): Chronic
106   II,     5.  8.  7    |          Henneberger P, Kreiss K, Mapp C, Milton D, Schwartz D, Toren
107   II,     5.  8.  7    |             Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles
108   II,     5.  8.  7    |           Kunzli N, Leynaert B, Janson C, Gislason T, Vermeire P,
109   II,     5.  8.  7    |         Gislason T, Vermeire P, Svanes C, Anto JM, Burney P (2004):
110   II,     5.  8.  7    |             125.~ ~Detournay B, Pribil C, Fournier M, Housset B,
111   II,     5.  8.  7    |               Huas D, Godard P, Voinet C, Chanal I, Jourdanne C,
112   II,     5.  8.  7    |          Voinet C, Chanal I, Jourdanne C, Durand-Zaleski I (2004):
113   II,     5.  8.  7    |                167: 418–424.~ ~Furhman C, Jougla E, Nicolauu J, Eilstein
114   II,     5.  8.  7    |                Aine T, Bakke P, Janson C (2007): Mortality in COPD
115   II,     5.  8.  7    |               Sobradillo V, Villasante C, Jimenez-Ruiz CA, Fernandez-Fau
116   II,     5.  8.  7    |              RL, Middelboe T, Pisinger C, Stage KB (2004): Anxiety
117   II,     5.  8.  7    |              Miravitlles M, de la Roza C, Morera J, Montemayor T,
118   II,     5.  8.  7    |           Shepherd R, Kee F, Patterson C, MacMahon J (2005): Prevalence
119   II,     5.  8.  7    |           McAuley S, Stewart A, Lamont C, Roseman P, Didsbury P (
120   II,     5.  8.  7    |             Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD
121   II,     5.  8.  7    |                S, Carrozzi L, Giuntini C (2000): Prevalence of airways
122   II,     5.  9.  7    |           Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P,
123   II,     5.  9.  7    |                    Jarvis D, Luczynska C, Chinn S, Potts J, Stunyer
124   II,     5.  9.  7    |             Potts J, Stunyer J, Janson C, Svanec C, Kunzly N, (2005):
125   II,     5.  9.  7    |            Stunyer J, Janson C, Svanec C, Kunzly N, (2005): Change
126   II,     5.  9.  7    |                Bettoncelli G, Cricelli C, Sessa E, Mazzaglia G, Canonica
127   II,     5.  9.  7    |             hcjz.hr~ ~Wang Y, McCusker C (2006): Neonatal exposure
128   II,     5. 10.  5    |         Soybeans and products thereof (c)~- Milk and products thereof (
129   II,     5. 10.  5    |             agent in beer and wine.~ ~(c) fully refined soybean oil
130   II,     5. 10.  7    | Cornelisse-Vermaat JR, Frewer L, Mills C, AEJ Dubois (2007): A framework
131   II,     5. 10.  7    |                1998.~Fasano A, Catassi C (2001): Current approaches
132   II,     5. 10.  7    |                EN, Valovirta E, Madsen C, Taylor SL, Vieths S, Anklam
133   II,     5. 10.  7    |              Beyer K, Frewer L, Madsen C, Botjes E, Crevel RWR, van
134   II,     5. 10.  7    |                Rona R, Keil T, Summers C, Gislason D, Zuidmeer L,
135   II,     5. 10.  7    |                 Van Eckert R, Feighery C, Janssen FW, Méndez E, Mothes
136   II,     5. 10.  7    |            Thomas K, Herouet-Guicheney C, Ladics G, Bannon G, Cockburn
137   II,     5. 10.  7    |                R, Fitzpatrick J, Mills C, Privalle L, Vieths S (2007):
138   II,     5. 11.  3    |            Point prevalence=3.6%~Mortz C, et al~Contact sensitisation~
139   II,     5. 11.  3    |              yrs)~Prevalence=15%~Mortz C, et al~Hand eczema~Swedish
140   II,     5. 11.  3    |               year prevalence=9%~Mortz C, et al~Psoriasis~Summary
141   II,     5. 11.  3    |             might affect work ability (C Lidén et al, 2001). Moreover,
142   II,     5. 11.  3    |             percentage of 25% in 1999 (C Lidén and K Norberg, 2005).
143   II,     5. 11.  3    |            Dermatitis,1985;13:289–293.~C Lidén, M Bruze, T Menné,
144   II,     5. 11.  3    |                Springer, 2001:935950.~C Lidén, K Norberg, Nickel
145   II,     5. 11.  3    |               236.~SH Nguyen, TP Dang, C Macpherson, H Maibach, HI
146   II,     5. 11.  7    |       University Press, 2003.~ ~Ceylan C, Ozturk G, Alper S (2003):
147   II,     5. 11.  7    |          London: HMSO, 1986.~ ~Schmied C, Saurat JH (1991): Epidemiology
148   II,     5. 11.  7    |            2002;147:716-24.~ ~Wassberg C, Thorn M, Johansson AM et
149   II,     5. 12.Acr    |        Hepatitis B virus~HCV~Hepatitis C virus~ICD~International
150   II,     5. 12.  1    |         disease, i.e., hepatitis B and C virus (HBV and HCV) infection
151   II,     5. 12.  4    |         disease, i.e., hepatitis B and C virus (HBV and HCV) infection (
152   II,     5. 12.  7    |                prevalence of hepatitis C virus infection in the United
153   II,     5. 12.  7    |            past incidence of hepatitis C virus infection: implications
154   II,     5. 12.  7    |        Hepatology 31:777-782.~ ~Bsetti C, Levi F, Lucchini F, Zatonski
155   II,     5. 12.  7    |                WA, Negri E, La Vecchia C (2007): Worldwide mortality
156   II,     5. 12.  7    |           combined action of hepatitis C virus infection and alcohol
157   II,     5. 12.  7    |               19:335-351.~ ~La Vecchia C, Levi F, Lucchini F, Franceschi
158   II,     5. 12.  7    |                4:480-486.~ ~La Vecchia C (2001): Alcohol in the Mediterranean
159   II,     5. 12.  7    |                 Boiocchi M, La Vecchia C, Franceschi S (2004): B-cell
160   II,     5. 12.  7    |               s lymphoma and hepatitis C virus infection: a systematic
161   II,     5. 12.  7    |                 Boudjema K, Vanlemmens C, Mantion G, Messner M, Launois
162   II,     5. 12.  7    |              epidemiology of hepatitis C virus infection. Lancet
163   II,     5. 14.  2    |             teeth, dentures or gums?~ ~c. Periodontal Health Assessment~
164   II,     5. 14.  8    |               Estupinan-Day S, NDiaye C (2005): The global burden
165   II,     5. 15.  6    |                Epub 2006 Jul 7.~McCabe C, Claxton K, Tsuchiya A (
166   II,     6.Acr        |               Infections~HCV~Hepatitis C Virus~HIB~Haemophilus Influenzae
167   II,     6.  3.  1    |         Chlamydia infection, hepatitis C, toxoplasmosis, to name
168   II,     6.  3.  3    |              addresses hepatitis B and C.~ ~Hepatitis B~ ~Hepatitis
169   II,     6.  3.  3    |            most countries.~ ~Hepatitis C~ ~Hepatitis C is the most
170   II,     6.  3.  3    |                Hepatitis C~ ~Hepatitis C is the most common type
171   II,     6.  3.  3    |                in the E.U.~ ~Hepatitis C is caused by the hepatitis
172   II,     6.  3.  3    |                caused by the hepatitis C virus (HCV), for which no
173   II,     6.  3.  3    |             more than 29 000 hepatitis C cases were reported by 24
174   II,     6.  3.  5    |             caused by serogroups B and C. Since 1999, several countries
175   II,     6.  3.  5    |           programmes against serogroup C disease, using a new conjugated
176   II,     6.  3.  5    |      introduction of the meningococcal C vaccine in high-risk populations.
177   II,     6.  4.  5    |               of antimicrobial agents; c) make sure that antibacterial
178   II,     7.  4.  2    |              these deaths (Figure 7.19.C). Injuries, at an advanced
179   II,     7.  4.  2    |               are taken.~ ~Figure 7.19.c. Fatal injuries by causes
180   II,     7.  7        |               2008].~ ~Guo B, Harstall C (2004). For which strategies
181   II,     7.  7        |          Health Organization.~ ~Körmer C, Smolka D (2008): Injuries
182   II,     7.  7        |                F, Eriksson L, Tingvall C, Villaveces A (2004): Preventing
183   II,     7.  7        |              Office for Europe.~ ~Todd C, Skelton D. (2004): What
184   II,     8.  2.  1    |                Morrison, J., Melville, C. Finlayson, J., Allan, L.,
185   II,     8.  2.  1    |                Emerson, E. and Hatton, C. (2007a). Contribution of
186   II,     8.  2.  1    |                Emerson, E. and Hatton, C. (2007b). Poverty, socio-economic
187   II,     8.  2.  1    |           Guidelines Limited.~Linehan, C., Walsh, P.N., et al., (
188   II,     8.  2.  1    |           Lantman-de Valk HMJ, Linehan C, Kerr MP, Walsh PN (2007):
189   II,     8.  2.  1    |               47~Walsh, P.N., Linehan, C., Kerr, M., van Schrojenstein
190   II,     8.  2.  1    |                 Azema, B., Aussilloux, C., Määttä, T., Salvador-Carulla,
191   II,     8.  2.  1    |          Kamper, M., Weber, G., Heiss, C., Haveman, M., Jørgensen,
192   II,     8.  2.  2    |            Lopez AD, Mathers CD, Stein C (2001): The Global Burden
193   II,     8.  2.  2    |             Available at: htt l.~Nucci C, Cedrone C, Culasso F, Ricci
194   II,     8.  2.  2    |                       Nucci C, Cedrone C, Culasso F, Ricci F, Cesareo
195   II,     8.  2.  3    |               33(6):395-402.~ ~Mathers C, Smith A, Concha M (2003):
196   II,     9.  1.  1    |     condition-specific registers.~ ~ ~(C=core, R=recommended, F=for
197   II,     9.  1.  1    |        development)~ ~Neonatal health~ C: Fetal mortality rate by
198   II,     9.  1.  1    |                birth weight, plurality~C: Neonatal mortality rate
199   II,     9.  1.  1    |                birth weight, plurality~C: Infant mortality rate by
200   II,     9.  1.  1    |                birth weight, plurality~C: birth weight distribution
201   II,     9.  1.  1    |             gestational age, plurality~C: Gestational age distribution
202   II,     9.  1.  1    |              policies~Maternal health~ C: Maternal mortality ratio
203   II,     9.  1.  1    |           characteristics/Risk factors~C: Multiple birth rate by
204   II,     9.  1.  1    |              rate by number of fetuses~C: Distribution of maternal
205   II,     9.  1.  1    |           Distribution of maternal age~C: Distribution of parity~
206   II,     9.  1.  1    |            origin~Health care services~C: Distribution of births
207   II,     9.  1.  1    |               Zhang W, Langer M, Vutuc C, Lindmark G (2003): Maternal
208   II,     9.  1.  1    |           DiLallo D, Spadea T, Perucci C. Cesarean (1992): section
209   II,     9.  1.  1    |             111 Suppl 1:S45-52.~ ~Cans C, Guillem P, Fauconnier J,
210   II,     9.  1.  1    |            Adams EK, Melvin CL, Kelsch C, Boulton ML (1999): Effects
211   II,     9.  1.  1    |             Farine D, Saigal S, Nimrod C, Kelly E, et al (2002):
212   II,     9.  1.  1    |          Hansen M, Kurinczuk JJ, Bower C, Webb S (2002): The risk
213   II,     9.  1.  1    |               3):451-7.~Platt MJ, Cans C, Johnson A, Surman G, Topp
214   II,     9.  1.  1    |                 Stephenson PA, Bakoula C, Hemminki E, Knudsen L,
215   II,     9.  1.  2    |                in case of infant death c) the likelihood that an
216   II,     9.  1.  2    |              sources of information.~ ~c) International Clearinghouse
217   II,     9.  1.  2    |            order to ascertain survival c) greater accuracy and accessibility
218   II,     9.  1.  2    |               even before pregnancy.~ ~c) Folic acid fortification
219   II,     9.  1.  2    |                Botto LD, Lisi A, Bower C, Canfield MA, Dattani N,
220   II,     9.  1.  2    |                MA, Dattani N, de Vigan C, de Walle H, Erickson EJ,
221   II,     9.  1.  2    |               Robert-Gnansia E, Siffel C, Stoll C and Mastroiacovo
222   II,     9.  1.  2    |      Robert-Gnansia E, Siffel C, Stoll C and Mastroiacovo P (2006): "
223   II,     9.  1.  2    |               J, Steinbicker V, Roesch C, McDonnell R, Scarano G,
224   II,     9.  1.  2    |            Dale I, Danaché B, De Vigan C, Fevotte J, Kiel G, Mandereau
225   II,     9.  1.  2    |               Queisser-LuftA, de Vigan C, Addor M-C, Gener B, Haeusler
226   II,     9.  1.  2    |              Jordan H, Tucker D, Stoll C, Feijoo M, Lillis D, Bianchi
227   II,     9.  1.  2    |                MC, Botting B, de Vigan C, de Walle H, Garne E, Loane
228   II,     9.  1.  2    |              Loane M, Dolk H, de Vigan C, Scarano G, Tucker D, Stoll
229   II,     9.  1.  2    |             Scarano G, Tucker D, Stoll C et al (2005): “Prenatal
230   II,     9.  1.  2    |             Garne E, Loane M, de Vigan C et al (2004): “Prenatal
231   II,     9.  1.  2    |                no. 33.~Hansen M, Bower C, Milne E, de Klerk N, Kurinczuk
232   II,     9.  1.  2    |            Lancet 338: 131-7.~Schaefer C, Garbis H, McElhatton P,
233   II,     9.  2.  7    |          Alexander D, Rigby M, Hillger C, Neumann G, Kirch W (2008):
234   II,     9.  2.  7    |             1976.~ ~Levi F, La Vecchia C, Negri E, Lucchini F (2001):
235   II,     9.  2.  7    |         Academy of Pediatrics~ ~Middle C, Johnson A, Alderdice F,
236   II,     9.  3.  1    |      Communicable diseases~ ~Hepatitis C. In Western Europe the prevalence
237   II,     9.  3.  1    |              EU enlargement, Hepatitis C was responsible for 30%
238   II,     9.  3.  1    |                   Boyle, P. Robertson, C. Mazzeha, C. Keech. M. Hobbs,
239   II,     9.  3.  1    |                 Robertson, C. Mazzeha, C. Keech. M. Hobbs, F.D.R.
240   II,     9.  3.  1    |          Fourcade R. Kiemeney , L, Lee C. and the UrEpik Study Group (
241   II,     9.  3.  1    |                 Fenton K A and Lowndes C M (2004): Recent trends
242   II,     9.  3.  1    |          Cancer Help UK (htt ~ ~Middle C, Johnson A, Alderdice F,
243   II,     9.  3.  2    |               Zhang W, Langer M, Vutuc C, Lindmark G (2003): Maternal
244   II,     9.  3.  2    |           DiLallo D, Spadea T, Perucci C. Cesarean (1992): section
245   II,     9.  3.  2    |             111 Suppl 1:S45-52.~ ~Cans C, Guillem P, Fauconnier J,
246   II,     9.  3.  2    |            Adams EK, Melvin CL, Kelsch C, Boulton ML (1999): Effects
247   II,     9.  3.  2    |             Farine D, Saigal S, Nimrod C, Kelly E, et al (2002):
248   II,     9.  3.  2    |          Hansen M, Kurinczuk JJ, Bower C, Webb S (2002): The risk
249   II,     9.  3.  2    |               392-5).~ ~Platt MJ, Cans C, Johnson A, Surman G, Topp
250   II,     9.  3.  2    |                 Stephenson PA, Bakoula C, Hemminki E, Knudsen L,
251   II,     9.  3.  3    |              the era of HIV, hepatitis C and other infections is
252   II,     9.  3.  3    |           References~ ~Amaro F, Frazão C, Pereire ME, da Cunha Teles
253   II,     9.  3.  3    |              Adolesc 28:535-40.~Currie C, Roberts C, Morgan A, Smith
254   II,     9.  3.  3    |              535-40.~Currie C, Roberts C, Morgan A, Smith R, Settertobultr
255   II,     9.  3.  3    |                INI)). Official Journal C 271 E , 12/11/2003 P. 0369 -
256   II,     9.  3.  3    |         federation of Finland.~Herlitz C, Ramstedt K (2005): Assessment
257   II,     9.  3.  3    |           ckm014v1-7~Johnson A, Mercer C, Erens B, et al (2001):
258   II,     9.  3.  3    |          Rundle K, Cousins G, Donnelly C, Mulcahy F, Conroy R (2006):
259   II,     9.  3.  3    |             Rev 2:CD001035.~Signorelli C, Pasquarella C, Limina RM,
260   II,     9.  3.  3    |              Signorelli C, Pasquarella C, Limina RM, Cozani E, Fanti
261   II,     9.  3.  3    |                AM, Cpas AJ, Korovessis C, fenton KA, Fiels J (2001):
262   II,     9.  5.  6    |               15(12):2494-501~ ~Middle C, Johnson A, Alderdice F,
263   II,     9.  5.  6    |          accessed 16.07.07)~ ~Paechter C (2003): Power, Bodies and
264  III,    10.  1.  3    |              10.1.3. References~Ambler C, Eliakim A, Brasel JA, Lee
265  III,    10.  1.  3    |               LJ, Milligan R, Thompson C (1995): Assessment of nutrition
266  III,    10.  1.  3    |            Gidding SS, Morgan W, Perry C, Isabel-Jones J, Bricker
267  III,    10.  1.  3    |           Kayser B, Saris WHM, Pichard C (2005): Effects of physical activity
268  III,    10.  1.  3    |               885-895.~Meusel D, Höger C, Pérez-Rodrigo C, Cavill
269  III,    10.  1.  3    |                 Höger C, Pérez-Rodrigo C, Cavill N, Armstrong T,
270  III,    10.  1.  3    |                 Keller I, Riley L, Roy C, Tukuitonga C (2006): A
271  III,    10.  1.  3    |             Riley L, Roy C, Tukuitonga C (2006): A framework to monitor
272  III,    10.  1.  3    |               49-61.~Parsons TJ, Power C, Logan S, Summerbell CD (
273  III,    10.  1.  3    |                205-8.~Tappy L, Binnert C, Schneiter Ph (2003): Energy
274  III,    10.  1.  3    |              Wagner N, Meusel D, Höger C, Kirch W (2005): health promotion
275  III,    10.  2.  1    |              tobacco_fr_en.pdf~ ~Bates C, Fagerström K, Jarvis MJ,
276  III,    10.  2.  1    |               Kvinnsland S, La Vecchia C, Levi F, McVie JC, Maisonneuve
277  III,    10.  2.  1    |         Richards M, Ringborg U, Scully C, Siracka E, Storm H, Tubiana
278  III,    10.  2.  1    |               2006; 25: 59-71~ ~Janson C, Künzli N, de Marco R, Chinn
279  III,    10.  2.  1    |              Chinn S, Jarvis D, Svanes C, Heinrich J, Jõgi R, Gislason
280  III,    10.  2.  1    |               M, Leynaert B, Luczynska C, Neukirch F, Vermeire P,
281  III,    10.  2.  1    |           James M, Jefferson T, Lushey C, Morleo M, Stokes E, Sumnall
282  III,    10.  2.  1    |                Campbell F, Schlesinger C, Heather N, Saunders J,
283  III,    10.  2.  1    |        Hepatitis B Virus~HCV~Hepatitis C Virus~IDU~Injecting Drug
284  III,    10.  2.  1    |                infected with hepatitis C virus in Europe. Regular
285  III,    10.  2.  1    |            infected with the hepatitis C virus in Europe.~ ~
286  III,    10.  2.  1    |           several countries. Hepatitis C infections among injecting
287  III,    10.  2.  1    |                caused by the hepatitis C virus (HCV), is much more
288  III,    10.  2.  1    |               Aids and hepatitis B and C) among drug users have triggered
289  III,    10.  2.  1    |          problems, including hepatitis C and HIV/AIDS, as well as
290  III,    10.  2.  1    |                 Ketley CE, Van Loveren C, Seppa L, Cochran JA, Polido
291  III,    10.  2.  1    |               Holbrook WP, van Loveren C, Fernandes B, Seppa L, Athanassouli
292  III,    10.  2.  1    |               Estupinan-Day S, NDiaye C. The global burden of oral
293  III,    10.  2.  1    |         Dahlgren H, Holm AK, Kallestal C, Lagerlof F, Lingstrom P,
294  III,    10.  2.  1    |              repository (see above).~ ~c) Reliable trend data~Bull
295  III,    10.  2.  1    |            Pratt M, Macera CA, Blanton C (1999): Levels of physical activity
296  III,    10.  2.  1    |   health-related behaviour. In: Currie C et al., eds. Young people’
297  III,    10.  2.  1    |              and physical activity (OJ C 250 E, 25.10.2007, p. 93~·
298  III,    10.  2.  1    |          Swedish).~ ~Bendixen H, Holst C, Sørensen TIA, Raben A,
299  III,    10.  2.  1    |               October 2007).~ ~Bromley C, Sproston K, Shelton N,
300  III,    10.  2.  1    |               October 2007).~ ~Bromley C, Sproston K, Shelton N,
301  III,    10.  2.  1    |                320:1240–1243.~ ~Currie C, Roberts C, Morgan A, Smith
302  III,    10.  2.  1    |              1243.~ ~Currie C, Roberts C, Morgan A, Smith R, Settertobulte
303  III,    10.  2.  1    |           Dolman R, Kingdon A, Roberts C, eds (2007): Welsh Health
304  III,    10.  2.  1    |             2007).~ ~Elgar FJ, Roberts C, Tudor-Smith C, Moore L (
305  III,    10.  2.  1    |                 Roberts C, Tudor-Smith C, Moore L (2005): Validity
306  III,    10.  2.  1    |               Nic Gabhainn S, Kelleher C (1999): The national health
307  III,    10.  2.  1    |               E, Apolone G, La Vecchia C (2006): Overweight and obesity
308  III,    10.  2.  1    |            Jackson-Leach R,  Mhurchu C, Kalamara E, Shayeghi M,
309  III,    10.  2.  1    |          Shayeghi M, Rigby NJ, Nishida C, Rodgers A (2004): Overweight
310  III,    10.  2.  1    |             Report 54:1-11.~ ~Kelleher C, Gabhainn SN, Friel S, Corrigan
311  III,    10.  2.  1    |             Publique 49:33-40.~ ~Padez C, Fernandes T, Mourão I,
312  III,    10.  2.  1    |            Biology 16:670-678.~ ~Power C (1994): Health and social
313  III,    10.  2.  1    |     Epiphaniou-Savva M, Chadjigeorgiou C, Kafatos A (2002): Obesity
314  III,    10.  2.  1    |           Tornaritis M, Chadjigeorgiou C, Kourides YA, Savva ME,
315  III,    10.  2.  1    |              Bartrina J, Pérez Rodrigo C, Saavedra Santana P, Peña
316  III,    10.  2.  1    |            October 2007).~ ~Summerbell C, Waters E, Edmunds LD, Kelly
317  III,    10.  2.  1    |            Europe 22(1):1-8.~ ~Gennari C (2001): Calcium and vitamin
318  III,    10.  2.  1    |              Miller AB, Kroke A, Bamia C, Karalis D, Vineis P, Palli
319  III,    10.  2.  1    |                D, Hjartaker A, Navarro C, Martinez GC, Wallstrom
320  III,    10.  2.  1    |            Welch AA, Spencer E, Stripp C, Overvad K, Clavel-Chapelon
321  III,    10.  2.  1    |          Clavel-Chapelon F, Casagrande C, Riboli E (2002): Consumption
322  III,    10.  2.  1    |                X, Berrino F, Sacerdote C, Ocke MC, Peeters PH, Engeset
323  III,    10.  2.  1    |               PH, Mulligan AA, Navarro C, Slimani N, Mattisson I,
324  III,    10.  2.  1    |              Tumino R, Navarro Sanchez C, Martinez Garcia C, Mattisson
325  III,    10.  2.  1    |             Sanchez C, Martinez Garcia C, Mattisson I, Nilsson S,
326  III,    10.  2.  1    |            Naska A, Sieri S, Sacerdote C, Ocke MC, Peeters PH, Skeie
327  III,    10.  2.  1    |                K, Tjonneland A, Stripp C, Clavel-Chapelon F, Kesse
328  III,    10.  2.  1    |          Masala G, Tumino R, Sacerdote C, Del Pezzo M, Bueno-de-Mesquita
329  III,    10.  2.  1    |             Boeing H, Kolyva M, Saieva C, Celentano E, Ocke MC, Peeters
330  III,    10.  2.  1    |               M, Rodriguez M, Lasheras C, Janzon L, Jansson J, Luben
331  III,    10.  2.  4    |                Dahm S, Nürnberg P, Roe C, Johnson J, Cox N J, Wichmann
332  III,    10.  2.  4    |                 Lewis JJ, Cordon-Cardo C (2001): Validation of tissue
333  III,    10.  2.  4    |          Ibarreta D, Bock, A.K., Klein C, Rodriguez-Cerezo E (2003):
334  III,    10.  2.  4    |               Leaderer B, Lai A, Spink C, Davis S, Bosch R, Scarpa
335  III,    10.  2.  4    |                  Sookoian SC, Gonzalez C, Pirola CJ (2005): Meta-analysis
336  III,    10.  2.  4    |             2131.~ ~Torhorst J, Bucher C, Kononen J, Haas P, Zuber
337  III,    10.  2.  5    |                JP, Porter M, McFarland C (2007): The relation of
338  III,    10.  2.  5    |               39.~ ~Barker DJP, Osmond C, Forsén TJ, Kajantie E,
339  III,    10.  2.  5    |              71.~ ~Eriksson JG, Osmond C, Kajantie E, Forsén TJ,
340  III,    10.  2.  5    |          Madigan S, Moran G, Schuengel C (2007): Unresolved maternal
341  III,    10.  2.  5    |               S, Roberts R, Cox A, Day C (2002) The European Early
342  III,    10.  2.  5    |           Wahlbeck K, Forsen T, Osmond C, Barker D, Eriksson J (2001):
343  III,    10.  3.  1    |                 Mäkeläinen I, Muirhead C, Oberaigner W, Pershagen
344  III,    10.  3.  1    |         Prüss-Üstün A, Zeeb H, Mathers C, RepacholiM (Eds.). Solar
345  III,    10.  3.  2    |            Forum. See: htt ~ ~Barbante C, et al (1999). Greenland
346  III,    10.  3.  2    |            Gomez, G Morrison, S Rauch, C McLeod, R Ma, S Caroli,
347  III,    10.  3.  2    |                 P Schramel, M Zischka, C Pettersson, U Wass, M Luna,
348  III,    10.  4.  2    |           spongiform encephalopathies; c) food hygiene: assure consistency
349  III,    10.  4.  2    |               requiring rapid action; (c) any rejection, related
350  III,    10.  4.  2    |        modified organisms (mainly Part C thereof);~· The placing
351  III,    10.  4.  2    |             any conflict of interest; (c) that adequate laboratory
352  III,    10.  4.  2    |             and responsibilities; and (c) the channels and procedures
353  III,    10.  5.  1    |              Mccarthy H, Oren R, Finzi C, EllsWorth DS, Jonshen KH,
354  III,    10.  5.  1    |      University Press) Oxford.~Michaud C, Murray C, Bloom B (2001):
355  III,    10.  5.  1    |              Oxford.~Michaud C, Murray C, Bloom B (2001): Burden
356  III,    10.  5.  3    |                Session 2006, Report I (C). ILO, Geneva. Available
357  III,    10.  6.  1    |                9): 1442-1445.~ ~Currie C, Gabhainn S, Godeau E, Roberts
358  III,    10.  6.  1    |          Gabhainn S, Godeau E, Roberts C, Smith R, Currie D, Picket
359  III,    10.  6.  2    |         Dalstra JAA, Kunst AE, Borrell C, Breeze E, Cambois E, Costa
360   IV,    11.  1.  3    |         systems with social insurance; c) separating purchasing from
361   IV,    11.  5.  4    |              HIV/AIDS, hepatitis B and C, bacteria, fungi and parasites
362   IV,    11.  6.  5    |           Barer ML, Evans RG, Hertzman C, Lomas J. (1987): "Aging
363   IV,    11.  6.  5    |               Malone J, Rüther A, Wild C. Best practice in undertaking
364   IV,    11.  6.  5    |                153: 1715-19.~ ~Castoro C, Bertinato L et al. (2007):
365   IV,    11.  6.  5    |            Policies.~ ~Chaix-Couturier C, Durand-Zaleski I et al. (
366   IV,    11.  6.  5    |             Durieux P, Chaix-Couturier C et al. (2000): "From clinical
367   IV,    11.  6.  5    |             Press.~ ~Hutton J, McGrath C et al. (2006): "Framework
368   IV,    11.  6.  5    |               Saltman, J. Figueras and C. Sakellarides. Buckingham,
369   IV,    11.  6.  5    |              22(3): 134-48.~ ~Masseria C, Koolman X et al. (2004):
370   IV,    11.  6.  5    |       Quarterly 62(4): 591-608.~ ~Shaw C (2003): How can hospital
371   IV,    11.  6.  5    |                3(2): 80-95.~ ~Sorenson C, Kanavos P et al. (2007):
372   IV,    11.  6.  5    |              van Doorslaer E, Masseria C et al. (2004): Income-related
373   IV,    12.  1        |          protection of public health;~(c) incentive measures designed
374   IV,    12. 10        |                      2006 Campaign: FA C T S A N D A D V I C E~about
375   IV,    12. 10        |                 FA C T S A N D A D V I C E~about smoking and stopping~http df~
376   IV,    12. 10        |            workplaces and at meetings.~C. “GetMoving” is an annual
377   IV,    12. 10        |                sozialen Brennpunkten E&C) htt ; In cooperation with
378   IV,    12. 10        |           delivered and managed.~ ~ ~ ~C) OTHER INFORMATION ON NATIONAL
379   IV,    12. 10        |           diseases (i.e. Hepatitis B & C, HPV, Syphilis, and Gonorrhea).